se ha leído el artículo
array:23 [ "pii" => "S0001731012700091" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70009-1" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70009" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:52-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1337 "formatos" => array:2 [ "HTML" => 710 "PDF" => 627 ] ] "itemSiguiente" => array:18 [ "pii" => "S0001731012700108" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70010-8" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70010" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:59-64" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1559 "formatos" => array:2 [ "HTML" => 778 "PDF" => 781 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab. Otros usos. Otras formas de psoriasis. Otras patologías cutáneas" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "64" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab. Other uses. Other forms of psoriasis. Other skin conditions" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Sánchez-Regaña" "autores" => array:1 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Sánchez-Regaña" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700108?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700108/v1_201304241722/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S000173101270008X" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70008-X" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70008" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:45-51" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1808 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 976 "PDF" => 831 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab en situaciones especiales: embarazo, interrupciones temporales (vacunaciones, cirugía) y otros" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "45" "paginaFinal" => "51" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab in special situations: pregnancy, temporal interruptions (vaccinations, surgery) and others" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Rivera, F. Vanaclocha" "autores" => array:2 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Rivera" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Vanaclocha" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101270008X?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S000173101270008X/v1_201304241722/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Manejo práctico de ustekinumab en la psoriasis moderada-grave" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "52" "paginaFinal" => "58" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Notario, X. Bordas" "autores" => array:2 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Notario" "email" => array:1 [ 0 => "jnotario@bellvitgehospital.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Bordas" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología. Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat. Barcelona. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Practical management of ustekinumab in moderate-severe psoriasis" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec85100" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Ustekinumab" 2 => "Fármacos biológicos" 3 => "Tratamiento combinado" 4 => "Tránsito tratamientos" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec85099" "palabras" => array:5 [ 0 => "Psoriasis" 1 => "Ustekinumab" 2 => "Biologic agents" 3 => "Combination therapy" 4 => "Treatment switch" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab (UST) es hasta la fecha el último fármaco biológico aprobado para el tratamiento de la psoriasis. En su manejo práctico nos son útiles tanto los trabajos con UST como la experiencia previa acumulada con otros agentes. Los estudios previos al tratamiento, así como su monitorización y seguimiento presentan semejanzas entre los diferentes fármacos biológicos. En otros aspectos como el tratamiento combinado o el tránsito entre tratamientos, la todavía corta experiencia con UST nos obliga a tomar decisiones según la práctica seguida con otros agentes biológicos.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El objetivo de este artículo es repasar algunos aspectos relacionados con el manejo práctico de UST incidiendo en características diferenciales del fármaco e intentar aprovechar el conocimiento de que disponemos con otras terapias biológicas para optimizar su uso.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Ustekinumab is the latest biologic agent to be approved for the treatment of psoriasis. Experience is therefore limited, but data from studies of ustekinumab can be complemented by experience with other biologic agents. While the guidelines for pretreatment screening and follow-up practices are similar in all of the biologic therapies, no standardized information on combination therapy or treatment switches is yet available for ustekinumab, and dermatologists thus have to base their decisions on experience with other biologic agents.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">This chapter discusses several aspects related to the use of ustekinumab in clinical practice. We focus on the distinguishing characteristics of this drug and discuss how our knowledge and experience with other biologic agents can be used to help optimize the use of ustekinumab.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:23 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ficha técnica de ustekinumab. (Consultado 16/07/2011). Disponible en: <a class="elsevierStyleInterRef" href="http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf">http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf</a>." ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Disponible en: <a class="elsevierStyleInterRef" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261lbl.pdf</a>." ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Schmitt" 1 => "Z. Zhang" 2 => "G. Wozel" 3 => "M. Meurer" 4 => "W. Kirch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08732.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "513" "paginaFinal" => "526" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18627372" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Puig" 1 => "E. Daudén" 2 => "J.M. Carrascosa" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "285" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20487683" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Puig" 1 => "X. Bordas" 2 => "J.M. Carrascosa" 3 => "E. Daudén" 4 => "C. Ferrándiz" 5 => "J.M. Hernanz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2009" "volumen" => "100" "paginaInicial" => "277" "paginaFinal" => "286" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19463230" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "(Chair of Guideline Group). British Association of Dermatologists’ guidelines for biologics interventions for psoriasis 2009" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.H. Smith" 1 => "A.V. Anstey" 2 => "J.N. Barker" 3 => "A.D. Burden" 4 => "R.J. Chalmers" 5 => "D.A. Chandler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09505.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2009" "volumen" => "161" "paginaInicial" => "987" "paginaFinal" => "1019" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19857207" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "National electronic Library for Medicines. Usketinumab. (Consultado 17/07/2011). Disponible en: <a class="elsevierStyleInterRef" href="http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/ustekinumab/">http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/ustekinumab/</a>." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of weight on the efficacy of biologic therapy in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Clark" 1 => "M. Lebwohl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.11.011" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "443" "paginaFinal" => "446" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18083274" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Lebwohl" 1 => "N. Yeilding" 2 => "P. Szapary" 3 => "Y. Wang" 4 => "S. Li" 5 => "Y. Zhu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.11.012" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2010" "volumen" => "63" "paginaInicial" => "571" "paginaFinal" => "579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20599293" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "A.B. Kimball" 2 => "K.A. Papp" 3 => "N. Yeilding" 4 => "C. Guzzo" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60725-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486739" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "R.G. Langley" 2 => "M. Lebwohl" 3 => "G.G. Krueger" 4 => "P. Szapary" 5 => "N. Yeilding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60726-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1675" "paginaFinal" => "1684" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486740" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Leonardi C, Sofen H, Yeilding N, Li S, Menter A. Maintenance of Long-term Efficacy of ustekinumab Through Year 3 for Patients with Moderate-to-severe Psoriasis. Poster (P589) presented at: 19th Congress of the European Academy of Dermatology and Venereology. Gotemburgo, 6–10 Oct 2010." ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estrategias para optimizar el tratamiento con efalizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.M. Carrascosa" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2008" "volumen" => "99" "numero" => "Suppl 1" "paginaInicial" => "37" "paginaFinal" => "50" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18341852" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Paul C, Puig L, Luger T, Lambert J, Chimenti S, Girolomoni G, et al. Ustekinumab is well-tolerated & effective in patients with psoriasis inadequately responsive to methotrexate: Week 12 results from the TRANSIT study. Aceptado como póster. XX Congreso AEDV. Lisboa, Oct 2011." ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.M. Downs" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2010.09832.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2010" "volumen" => "163" "paginaInicial" => "433" "paginaFinal" => "434" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20456344" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Q.U. Kamili" 1 => "A. Miner" 2 => "A. Hapa" 3 => "A. Menter" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2011" "volumen" => "10" "paginaInicial" => "539" "paginaFinal" => "544" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21533302" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept combined with methotrexate for high-need psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.J. Driessen" 1 => "P.C. Van de Kerkhof" 2 => "E.M. De Jong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08669.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "460" "paginaFinal" => "463" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18547310" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Zachariae" 1 => "N.J. Mørk" 2 => "T. Reunala" 3 => "H. Lorentzen" 4 => "E. Falk" 5 => "S.L. Karvonen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-0511" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2008" "volumen" => "88" "paginaInicial" => "495" "paginaFinal" => "501" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18779890" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Unite Study Group" "etal" => true "autores" => array:6 [ 0 => "L. Kircik" 1 => "J. Bagel" 2 => "N. Korman" 3 => "A. Menter" 4 => "C.A. Elmets" 5 => "J. Koo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2008" "volumen" => "7" "paginaInicial" => "245" "paginaFinal" => "253" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18380206" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigatorblinded pilot trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Gisondi" 1 => "M. Del Giglio" 2 => "C. Cotena" 3 => "G. Girolomoni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08564.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "158" "paginaInicial" => "1345" "paginaFinal" => "1349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18410408" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combining systemic retinoids with biologic agents for moderate to severe psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E.C. Smith" 1 => "C. Riddle" 2 => "M.A. Menter" 3 => "M. Lebwohl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2008.03470.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "514" "paginaFinal" => "518" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18412874" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Gottlieb" 1 => "A. Menter" 2 => "A. Mendelsohn" 3 => "Y.K. Shen" 4 => "S. Li" 5 => "C. Guzzo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(09)60140-9" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2009" "volumen" => "373" "paginaInicial" => "633" "paginaFinal" => "640" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19217154" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Ustekinumab Crohn's Disease Study Group" "etal" => true "autores" => array:6 [ 0 => "W.J. Sandborn" 1 => "B.G. Feagan" 2 => "R.N. Fedorak" 3 => "E. Scherl" 4 => "M.R. Fleisher" 5 => "S. Katz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2008.07.014" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2008" "volumen" => "135" "paginaInicial" => "1130" "paginaFinal" => "1141" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18706417" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700091/v1_201304241722/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/00000103000000S2/v1_201304241722/S0001731012700091/v1_201304241722/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700091?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 3 | 13 | 16 |
2024 Octubre | 23 | 42 | 65 |
2024 Septiembre | 23 | 23 | 46 |
2024 Agosto | 40 | 54 | 94 |
2024 Julio | 28 | 40 | 68 |
2024 Junio | 29 | 39 | 68 |
2024 Mayo | 29 | 32 | 61 |
2024 Abril | 20 | 21 | 41 |
2024 Marzo | 27 | 50 | 77 |
2024 Febrero | 22 | 31 | 53 |
2024 Enero | 16 | 33 | 49 |
2023 Diciembre | 14 | 20 | 34 |
2023 Noviembre | 17 | 34 | 51 |
2023 Octubre | 19 | 25 | 44 |
2023 Septiembre | 16 | 24 | 40 |
2023 Agosto | 13 | 12 | 25 |
2023 Julio | 17 | 30 | 47 |
2023 Junio | 8 | 25 | 33 |
2023 Mayo | 4 | 11 | 15 |
2023 Abril | 22 | 23 | 45 |
2023 Marzo | 12 | 38 | 50 |
2023 Febrero | 16 | 20 | 36 |
2023 Enero | 16 | 34 | 50 |
2022 Diciembre | 23 | 36 | 59 |
2022 Noviembre | 12 | 22 | 34 |
2022 Octubre | 18 | 32 | 50 |
2022 Septiembre | 14 | 62 | 76 |
2022 Agosto | 16 | 52 | 68 |
2022 Julio | 27 | 66 | 93 |
2022 Junio | 10 | 40 | 50 |
2022 Mayo | 26 | 53 | 79 |
2022 Abril | 21 | 48 | 69 |
2022 Marzo | 18 | 49 | 67 |
2022 Febrero | 17 | 38 | 55 |
2022 Enero | 23 | 41 | 64 |
2021 Diciembre | 16 | 50 | 66 |
2021 Noviembre | 22 | 48 | 70 |
2021 Octubre | 21 | 57 | 78 |
2021 Septiembre | 15 | 55 | 70 |
2021 Agosto | 28 | 37 | 65 |
2021 Julio | 28 | 54 | 82 |
2021 Junio | 15 | 32 | 47 |
2021 Mayo | 15 | 44 | 59 |
2021 Abril | 45 | 49 | 94 |
2021 Marzo | 27 | 36 | 63 |
2021 Febrero | 24 | 38 | 62 |
2021 Enero | 20 | 30 | 50 |
2020 Diciembre | 16 | 11 | 27 |
2020 Noviembre | 15 | 21 | 36 |
2020 Octubre | 9 | 16 | 25 |
2020 Septiembre | 7 | 10 | 17 |
2020 Agosto | 11 | 29 | 40 |
2020 Julio | 7 | 19 | 26 |
2020 Junio | 16 | 15 | 31 |
2020 Mayo | 19 | 35 | 54 |
2020 Abril | 9 | 12 | 21 |
2020 Marzo | 9 | 19 | 28 |
2019 Diciembre | 0 | 3 | 3 |
2019 Noviembre | 0 | 8 | 8 |
2019 Octubre | 0 | 1 | 1 |
2019 Agosto | 0 | 3 | 3 |
2019 Julio | 0 | 5 | 5 |
2019 Junio | 0 | 7 | 7 |
2019 Mayo | 0 | 13 | 13 |
2019 Abril | 0 | 2 | 2 |
2019 Marzo | 0 | 1 | 1 |
2019 Febrero | 0 | 5 | 5 |
2018 Diciembre | 0 | 2 | 2 |
2018 Noviembre | 0 | 5 | 5 |
2018 Octubre | 0 | 1 | 1 |
2018 Marzo | 1 | 0 | 1 |
2018 Febrero | 13 | 3 | 16 |
2018 Enero | 9 | 5 | 14 |
2017 Diciembre | 23 | 7 | 30 |
2017 Noviembre | 9 | 4 | 13 |
2017 Octubre | 13 | 9 | 22 |
2017 Septiembre | 5 | 13 | 18 |
2017 Agosto | 8 | 13 | 21 |
2017 Julio | 10 | 3 | 13 |
2017 Junio | 19 | 56 | 75 |
2017 Mayo | 18 | 17 | 35 |
2017 Abril | 23 | 7 | 30 |
2017 Marzo | 19 | 27 | 46 |
2017 Febrero | 17 | 5 | 22 |
2017 Enero | 17 | 14 | 31 |
2016 Diciembre | 23 | 7 | 30 |
2016 Noviembre | 25 | 5 | 30 |
2016 Octubre | 42 | 13 | 55 |
2016 Septiembre | 35 | 14 | 49 |
2016 Agosto | 35 | 26 | 61 |
2016 Julio | 27 | 20 | 47 |
2016 Junio | 0 | 12 | 12 |
2016 Mayo | 1 | 20 | 21 |
2016 Abril | 0 | 3 | 3 |
2016 Marzo | 0 | 3 | 3 |
2016 Febrero | 0 | 3 | 3 |
2016 Enero | 1 | 25 | 26 |
2015 Diciembre | 2 | 14 | 16 |
2015 Noviembre | 5 | 21 | 26 |
2015 Octubre | 5 | 13 | 18 |
2015 Septiembre | 2 | 12 | 14 |
2015 Agosto | 2 | 8 | 10 |
2015 Julio | 26 | 2 | 28 |
2015 Junio | 25 | 14 | 39 |
2015 Mayo | 42 | 22 | 64 |
2015 Abril | 37 | 16 | 53 |
2015 Marzo | 35 | 10 | 45 |
2015 Febrero | 35 | 13 | 48 |
2015 Enero | 25 | 13 | 38 |
2014 Diciembre | 19 | 22 | 41 |
2014 Noviembre | 26 | 16 | 42 |
2014 Octubre | 22 | 25 | 47 |
2014 Septiembre | 0 | 1 | 1 |
2014 Agosto | 1 | 0 | 1 |
2014 Julio | 0 | 1 | 1 |
2014 Febrero | 1 | 0 | 1 |
2014 Enero | 1 | 2 | 3 |
2013 Octubre | 1 | 0 | 1 |
2013 Septiembre | 0 | 1 | 1 |
2013 Junio | 2 | 4 | 6 |
2013 Mayo | 1 | 2 | 3 |
2013 Abril | 1 | 1 | 2 |
2013 Marzo | 1 | 1 | 2 |
2013 Febrero | 0 | 2 | 2 |
2013 Enero | 0 | 1 | 1 |